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 STEMI remains a signiﬁcant cause of
in-hospital mortality, and up to 20% of
people go on to develop heart failure.
 P188 is a nonionic triblock copolymer
believed to prevent cellular injury afterischemia and reperfusion. The CORE trial
examined P188 for STEMI patients showing
no beneﬁt when it was infused through a
peripheral IV catheter approximately 30 min
after revascularization with thrombolytic
therapy.
 STEMI was induced in pigs using endovascular
coronary artery occlusion to compare
intracoronary infusion of P188 immediately
after revascularization to infusion of P188
through a peripheral IV catheter 30 min after
revascularization. Immediate intracoronary
infusion of vehicle control and PEG, a
rheological control, were also compared.
 Intracoronary infusion of P188 immediately
upon reperfusion reduced infarct size by
68% compared with delayed peripheral
P188 infusion, which was similar to vehicle
control.
 Mitochondrial respiration and calcium stress
tolerance were preserved in the ischemic
tissue of pigs treated with immediate
intracoronary P188 infusion. Mitochondria
from pigs with delayed peripheral P188
infusion were no different from control pigs.
 By reducing infarct size and mitochondrial
dysfunction, immediate intracoronary
infusion of P188 may provide a therapeutic
strategy to improve post-STEMI outcomes.
The timing and route of delivery were critical
to the observed beneﬁt.
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225SUMMARY
AB BAND ACRONYM S
IC = intracoronary
IV = intravenous
P188 = poloxamer 188
PEG = polyethylene glycol
STEMI = ST-segment elevation
myocardial infarction
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MaPoloxamer 188 (P188) is a nonionic triblock copolymer believed to prevent cellular injury after ischemia and
reperfusion. This study compared intracoronary (IC) infusion of P188 immediately after reperfusion with delayed
infusion through a peripheral intravenous catheter in a porcine model of ST-segment elevation myocardial
infarction (STEMI). STEMI was induced in 55 pigs using 45 min of endovascular coronary artery occlusion. Pigs
were then randomized to 4 groups: control, immediate IC P188, delayed peripheral P188, and polyethylene glycol
infusion. Heart tissue was collected after 4 h of reperfusion. Assessment of mitochondrial function or infarct size
was performed. Mitochondrial yield improved signiﬁcantly with IC P188 treatment compared with control ani-
mals (0.25% vs. 0.13%), suggesting improved mitochondrial morphology and survival. Mitochondrial respiration
and calcium retention were also signiﬁcantly improved with immediate IC P188 compared with control animals
(complex I respiratory control index: 7.4 vs. 3.7; calcium retention: 1,152 nmol vs. 386 nmol). This beneﬁt was
only observed with activation of complex I of the mitochondrial respiratory chain, suggesting a speciﬁc effect
from ischemia and reperfusion on this complex. Infarct size and serum troponin I were signiﬁcantly reduced by
immediate IC P188 infusion (infarct size: 13.9% vs. 41.1%; troponin I: 19.2 mg/l vs. 77.4 mg/l). Delayed P188 and
polyethylene glycol infusion did not provide a signiﬁcant beneﬁt. These results demonstrate that intracoronary
infusion of P188 immediately upon reperfusion signiﬁcantly reduces cellular and mitochondrial injury after
ischemia and reperfusion in this clinically relevant porcine model of STEMI. The timing and route of delivery
were critical to achieve the beneﬁt. (J Am Coll Cardiol Basic Trans Science 2016;1:224–34) © 2016 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).C oronary heart disease accounts for 1 of 6deaths each year in the United States, withan estimated 595,000 people experiencing
myocardial infarction, of whom approximately 30%
experience ST-segment elevation myocardial infarc-
tion (STEMI) (1). STEMI leads to in-hospital mortality
in 6% of cases, and 13% to 20% of people go on to
develop heart failure (2). STEMI-induced injury
occurs in 2 stages. The ﬁrst stage, ischemic injury,
varies in severity depending on the pre-ischemic con-
dition of the tissue, the duration of the ischemia, and
the degree of revascularization. The second stage,
reperfusion injury, is the injury initiated when blood
ﬂow returns to the ischemic tissue (3–5). Multiple cell
injury pathways are thought to contribute to reperfu-
sion injury, including membrane destabilization,
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226the standard of care for patients with STEMI,
providing additional opportunities for treatment of
myocardial injury.
We hypothesized that P188 would prevent reper-
fusion injury and reduce infarct size when infused
immediately upon reperfusion with localized delivery
into the coronary artery. We tested this in the clini-
cally relevant setting of coronary angioplasty. We
further hypothesized that recreating the treatment
conditions of the CORE trial with delayed infusion of
the same dose of P188 through a peripheral intrave-
nous (IV) catheter would demonstrate no beneﬁt.ion of the Experimental Groups
esentation of the experimental protocols. Infarction was produced
vascular coronary occlusion. Treatment began at reperfusion in the
EG groups with intracoronary (IC) infusion of saline (1.7 ml/kg), P188
(250 mg/kg), respectively, over 30 min. The delayed P188 group
(IV) P188 infusion (250 mg/kg) beginning 30 min after reperfusion
ceived an intravenous maintenance infusion of the respective therapy
trol or 250 mg/kg for all others) lasting 3 h. Hearts were harvested at
for further analysis. (B) The sample size is shown for each treatment
the mitochondrial and infarct size analysis groups.METHODS
All studies were performed with approval from the
Institutional Animal Care and Use Committee of
the Minneapolis Medical Research Foundation and
the National Research Council’s 1996 Guidelines
for the Care and Use of Laboratory Animals (Protocol
15-02-03).
ANIMAL MODEL. Yorkshire pigs, 38 to 42 kg, were
used for all studies. The anesthesia, surgical prepara-
tion, and data monitoring and recording were per-
formed as described in detail previously (14). Brieﬂy,
pigs were anesthetized with ketamine (10 ml of 100
mg/ml) followed by inhaled isoﬂurane at a dose of
0.8% to 1.2% for the remainder of the study. Animals
were intubated with a 7.0-mm endotracheal tube.
Temperature was measured with an esophageal tem-
perature probe and was maintained at 37.5  0.5C
with a warming blanket throughout the study.
Vascular access was obtained in the bilateral femoral
arteries with 8-F sheaths placed percutaneously under
ultrasound guidance. An 8-F sheath was placed in the
right external jugular vein. A right ear vein IV catheter
was placed. The central aortic pressure was monitored
continuously with a micromanometer-tipped catheter
(Millar Instruments, Houston, Texas) placed through
the left femoral sheath, and the right atrial pressure
was measured with a second micromanometer-tipped
catheter placed in the right external jugular sheath. All
animals received an IV heparin bolus (100 U/kg) and
1,000 U heparin every 2 h thereafter. The animals were
ventilated with room air using volume-controlled
ventilation (Narkomed, Draeger Medical, Telford,
Pennsylvania) with tidal volume of 10 ml/kg and a
respiratory rate adjusted to maintain PaCO2 of
40mmHg and arterial O2 saturation>95% asmeasured
from arterial blood (Gem 300, Instrumentation Labo-
ratory, Bedford, Massachusetts). Surface electrocar-
diographic tracings were continuously recorded. All
data were recorded with a BIOPAC digital acquisition
system (BIOPAC Systems Inc., Goleta, California).
EXPERIMENTAL PROTOCOLS. Animals (n ¼ 55) were
randomized into 1 of 4 treatment groups: control,
P188, delayed P188, and polyethylene glycol (PEG)
8,000 Da. Each treatment group was further divided
into 2 groups: mitochondrial studies or assessment of
infarct size (Figure 1). The protocol details were
described previously (15) and are described brieﬂy in
the following text.
Blood v iscos i ty assessment . Arterial blood was
collected from animals prior to ischemia. Heparin was
added (10 U/ml) to prevent thrombus formation.
Hematocrit was measured at 28%. Blood was added to
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227an AR-G2 rheometer with a couette attachment (TA
Instruments, New Castle, Delaware). Viscosity was
assessed at 37C with varied shear rate ranging from
0.1 to 100 s1. Measurements were repeated at various
concentrations of P188 and PEG.
Percutaneous coronary occ lus ion . The left main
coronary artery was engaged with a 6-F AL 0.75
guide (Cordis, Fremont, California) advanced from the
right femoral sheath with ﬂuoroscopic guidance
(OEC 9800, General Electric, Fairﬁeld, Connecticut).
Coronary angiography was performed with injection
of Omnipaque contrast (GE Healthcare, Dublin,
Ireland). For mitochondrial studies, a 0.014-inch
guidewire was passed through the left circumﬂex ar-
tery into the second obtuse marginal branch, over
which a 2.75  8 mm monorail bare-metal stent
(Abbott Vascular, Abbott Park, Illinois) was inserted.
The balloon was inﬂated, thereby deploying the stent
and occluding the vessel. For infarct size studies, a
0.014-inch guidewire was inserted into the left ante-
rior descending (LAD) artery and a 2.75  8 mm
monorail balloon (Medtronic, Minneapolis, Minne-
sota) was advanced distal to the second diagonal
branch. The balloon was inﬂated occluding ﬂow but
allowing ﬂow to the second diagonal.
In all studies, vessel occlusion was veriﬁed with
intracoronary (IC) contrast injection showing no pas-
sage beyond the balloon. The guide was disengaged
from the left main coronary artery to prevent restric-
tion of ﬂow to the entire left coronary circulation. The
vessel remained occluded for 45 min. The animal was
then treated with 40 mg amiodarone IV, the guide was
reinserted into the left main coronary artery, and the
balloon was deﬂated and removed. A brief coronary
angiogram was performed to verify coronary blood
ﬂow to the ischemic territory. P188, PEG, or saline
vehicle control were delivered as indicated (Figure 1).
Arrhythmia, including ventricular tachycardia and
ventricular ﬁbrillation, were treated with deﬁbrilla-
tion as needed. All animals achieved return of spon-
taneous circulation and completed 4 h of reperfusion
time.
I so lat ion of mitochondr ia . After 4 h of reperfusion,
animals were euthanized and the heart was removed.
Tissue was excised from the area of the second obtuse
marginal branch distal to the stent (infarct) as well as
the area adjacent to the LAD (nonischemic).
Mitochondrial experiments were performed as
described previously (16). Brieﬂy, excised cardiac
tissue was immediately placed in ice cold isolation
buffer containing 200 mmol/l mannitol, 50 mmol/l
sucrose, 5 mmol/l KH2PO4, 5 mmol/l 3-(n-morpholino)
propanesulfonic acid (MOPS), 1 mmol/l ethylene gly-
col tetraacetic acid, and 0.1% bovine serum albumin(BSA), pH 7.15. The tissue was then manually minced
and homogenized with a blade homogenizer (CAT
Scientiﬁc, Paso Robles, California) in the presence of
5 U/ml protease (Bacillus licheniformis). The protease
was then diluted 10-fold, and homogenization was
repeated. Mitochondria were isolated by differential
centrifugation including 10 min at 8,000  g followed
by resuspension of the pellet and centrifugation at
750  g for 10 min to remove cellular debris. Isolated
mitochondria were quantiﬁed by Bradford protein
quantiﬁcation assay (Sigma, St. Louis, Missouri). The
mitochondrial yield was calculated as the ratio of
total protein mass of isolated mitochondrial to total
protein mass of the excised heart tissue from which
they were isolated.
Mitochondr ia l resp i rat ion . Mitochondrial oxygen
consumption was measured at 25C using a Clark-type
O2 electrode (Model 1302, Strathkelvin Instruments,
North Lanarkshire, Scotland) in a water-jacketed
chamber. Mitochondria (275 mg) were added to the
respiration chamber with experimental buffer con-
taining 130 mmol/l KCl, 5 mmol/l K2HPO4, 20 mmol/l
MOPS, and 0.1% BSA, pH 7.15. State 2 respiration was
initiated with the addition of substrate speciﬁc for
either complex I (10 mmol/l pyruvate/malate) or
complex II (10 mmol/l succinate and 10 mmol/l rote-
none, a complex I blocker) of the mitochondrial
respiratory chain. State 3 respiration then began with
addition of 250 mmol/l adenosine diphosphate. State
4 was observed when the phosphorylation of adeno-
sine diphosphate to adenosine triphosphate was
complete. The respiratory control index (RCI) was
calculated as the ratio of state 3 to 4 respiration.
Mitochondr ia l ca lc ium retent ion . Mitochondria
(0.5 mg/ml) were combined with complex I (10
mmol/l pyruvate/malate) or complex II (10 mmol/l
succinate and 10 mmol/l rotenone) substrates and
buffer containing 130 mmol/l KCl, 5 mmol/l K2HPO4,
20 mmol/l MOPS, and 0.1% BSA, pH 7.15. CaGreen-5N
hexapotassium salt (100 nmol/l) was added to
monitor extra-mitochondrial calcium at excitation
510 nm and emission 531 nm (Life Technologies,
Grand Island, New York). CaCl2 (5 mmol/l) was
infused at a rate of 150 nmol/min until the CaGreen
ﬂuorescence reached steady state. A sudden increase
in CaGreen emission suggested an opening of the
mitochondrial permeability transition pore (mPTP).
The calcium retention capacity is quantiﬁed as the
calcium required to trigger mPTP opening.
In farct s i ze assessment . After 4 h of reperfusion,
the left main coronary artery was again engaged with
a 6-F AL 0.75 guide. The right coronary artery was
engaged with a 6-F hockey stick guide. The 0.014-
inch guidewire was again advanced into the LAD,
FIGURE 2 Blood Viscosity With Addition of PEG and P188
Blood viscosity was measured at increasing shear rates with various concentrations of
PEG or P188. All data points represent n ¼ 4. Error bars represent SEM. Statistical sig-
niﬁcance (p < 0.05) denoted as: *comparing PEG and P188 at shear rate 0.1 s1;
†comparing shear rate 0.1 s1 vs. 1, 10, and 100 s1 for PEG; ††comparing shear rate 0.1 s1
vs. 1, 10, and 100 s1 for P188; #comparing shear rate 1 s1 vs. 10 and 100 s1 for PEG and
P188; and ##comparing shear rate 0.1 s1 vs. 100 s1 for PEG. Abbreviations as in Figure 1.
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228over which a 3.0  8 mm over-the-wire balloon was
inserted distal to the second diagonal branch in the
same position as the prior balloon as veriﬁed by
ﬂuoroscopy. The balloon was inﬂated, the guidewire
was removed, and 40 ml of 2% 2,3,5 triphenylte-
trazolium chloride was infused through the lumen of
the balloon catheter. Subsequently, 60 ml of 1% Evans
Blue dye (Sigma) was infused in each of the 2 guides
perfusing the left main coronary artery and right
coronary artery simultaneously. These infusions
induced ventricular ﬁbrillation. The heart was then
excised and sliced in 1-cm-thick slices from the apex
to the base of the heart. Each side of the slice was
photographed. The infarct (white) and area at
risk (red) were quantiﬁed using ImageJ (National
Institutes of Health, Bethesda, Maryland).
Troponin and creatinine assessment. Arterial blood
was collected prior to infarction and after 4 h of
reperfusion. Cardiac-speciﬁc troponin I (cTnI) was
quantiﬁed using a 2-site sandwich assay (Stratus CS
Acute Care, Siemens, Munich, Germany). Creatinine
was measured with standard human assays. Personnel
performing the analysis were blinded to the treatment.
STATISTICAL ANALYSIS. Values are expressed as
mean  SE of the mean. All statistics were performed
with GraphPad Prism 6 (GraphPad Software, La Jolla,
California). The data were normality tested with the
D’Agostino-Pearson omnibus test indicating that all
datasets were sufﬁciently normally distributed.
Rheology data were compared between shear rates
using a repeated measures analysis of variance with
the Fisher Least Signiﬁcant Difference post-hocanalysis. Comparisons of mitochondrial yield, RCI,
and calcium retention capacity between infarct and
nonischemic tissues were performed using paired
Student t tests with multiplicity adjustment using the
Holm-Sidak method. All other data were compared
using a 1- or 2-way analysis of variance as appropriate
and Fisher Least Signiﬁcant Difference post-hoc
analysis. A 2-tailed p value <0.05 was considered
statistically signiﬁcant.
RESULTS
INFLUENCE OF P188 AND PEG ON BLOOD VISCOSITY.
PEG was chosen as a viscosity control for P188 on the
basis of molecular weight and similar composition;
however, the effect of PEG on blood viscosity was not
well described. As shown in Figure 2, the addition
of increasing concentrations of PEG and P188 resulted
in similar reductions in whole blood viscosity.
Increasing the shear rate reduced the whole blood
viscosity independent of P188 and PEG, partially
negating the effect of PEG and P188. At low shear
rates, high-dose P188 (9 mg/ml) reduced viscosity to a
modestly lesser degree compared with PEG (0.023
Pa$s vs. 0.011 Pa$s; p < 0.001). The viscosity effects of
P188 and PEG were otherwise similar.
MITOCHONDRIAL YIELD IMPROVES WITH P188
TREATMENT. Isolation ofmitochondria by differential
centrifugation requires intact mitochondria of stable
density. Therefore, reductions in mitochondrial yield
suggest loss of membrane integrity (i.e., rupture) or
substantial change in morphology (i.e., swelling and
destabilization). Although mitochondrial yield was
reduced in the infarct territory of all groups, IC P188
signiﬁcantly improved the yield of mitochondria iso-
lated compared with control animals (0.25% vs. 0.13%;
p ¼ 0.012) (Figure 3). In contrast, delayed P188
demonstrated no signiﬁcant improvement over con-
trol animals (0.17% vs. 0.13%; p ¼ 0.45). Intracoronary
PEG demonstrated no signiﬁcant difference compared
with control animals (0.16% vs. 0.13%; p ¼ 0.57).
MITOCHONDRIAL FUNCTION IS PRESERVED WITH
P188 TREATMENT. The central role of mitochondria is
respiration resulting in synthesis of adenosine
triphosphate. The RCI using substrates speciﬁc for
complex I of the mitochondrial respiratory chain was
signiﬁcantly lower in infarct tissue from control ani-
mals, delayed P188, and PEG animals compared with
noninfarct tissue (3.7 vs. 8.2, 3.9 vs. 8.2, 4.2 vs. 9.3,
respectively; p < 0.001) (Figure 4A). In contrast, the
complex I RCI of infarct tissue from P188-treated ani-
mals was signiﬁcantly higher compared with control
animals (7.4 vs. 3.7; p < 0.001). Further, it was not
statistically different compared with nonischemic
FIGURE 3 Mitochondrial Yield
The yield of isolated mitochondria was calculated as the ratio of
total protein in the maximally enriched isolated mitochondrial
fraction compared with the tissue mass homogenized at the start
of the isolation. Control (n ¼ 8), P188 (n ¼ 10), delayed P188
(n ¼ 6), and PEG (n ¼ 6) were compared as indicated. Error bars
represent SEM. Statistical signiﬁcance (p < 0.05) denoted as:
*comparing infarct to nonischemic territory from the same
treatment group, and #comparing infarct tissue harvested from
the P188 group to infarct tissue from all other groups. Abbre-
viations as in Figure 1.
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229tissue (7.4 vs. 8.2; p ¼ 0.85), suggesting near total
preservation of mitochondrial respiration through
complex I. Complex I RCI for infarct tissue from
delayed P188 and PEG-treated animals were similar to
infarct tissue from control animals (3.9 and 4.2 vs.
3.7 for delayed P188 [p ¼ 0.85] and PEG [p ¼ 0.61],
respectively).FIGURE 4 Respiratory Control Index of Isolated Mitochondria
The respiratory control index is deﬁned as the ratio of state 3 to 4 respir
(n ¼ 6) groups were compared as indicated. Complex I substrates (A) a
Statistical signiﬁcance (p < 0.05) denoted as: *comparing infarct to non
infarct tissue harvested from the P188 group with infarct tissue from alComplex II RCI was signiﬁcantly reduced for
mitochondria isolated from infarct tissue in all
treatment groups when compared with nonischemic
tissue (2.1 vs. 3.4, 2.7 vs. 3.5, 2.2 vs. 3.9, 2.3 vs. 3.8
for control, P188, delayed P188, and PEG, respec-
tively; p < 0.01) (Figure 4B). There were no signif-
icant differences between the treatment groups
when comparing ischemic tissues or nonischemic
tissues.
Calcium retention, a measure of mitochondrial
membrane integrity and mitochondrial function,
was signiﬁcantly reduced in the infarct tissue of all
groups in the presence of complex I substrates when
compared with nonischemic tissue (Figure 5A). How-
ever, calcium retention of mitochondria isolated from
P188-treated animals was signiﬁcantly preserved
compared with control, delayed P188, and PEG ani-
mals (1,152 nmol vs. 386, 451, and 423 nmol, respec-
tively; p < 0.001).
In the setting of complex II substrates, mitochon-
dria isolated from the infarct territory of P188-treated
animals continued to tolerate higher levels of calcium
compared with control, delayed P188, and PEG
animals (1,481 nmol vs. 848, 843, and 881 nmol,
respectively; p < 0.005) (Figure 5B). However, mito-
chondria from infarct tissue from P188-treated
animals also retained signiﬁcantly greater levels of
calcium than the nonischemic mitochondria from
P188-treated animals (1,481 vs. 1,005 nmol; p ¼
0.019). There were no signiﬁcant differences in cal-
cium retention capacity of the mitochondria taken
from control, delayed P188, and PEG animals when
infarct and nonischemic tissues were compared.ation. Control (n ¼ 8), P188 (n ¼ 10), delayed P188 (n ¼ 6), and PEG
nd complex II substrates (B) were used. Error bars represent SEM.
ischemic territory from the same treatment group, and #comparing
l other groups. Abbreviations as in Figure 1.
FIGURE 5 Calcium Retention Capacity of Isolated Mitochondria
The cumulative calcium infused up to the point of mitochondrial permeability transition pore opening is compared for control (n¼ 8), P188 (n¼
10), delayed P188 (n ¼ 6), and PEG (n ¼ 6) groups as indicated. Substrates speciﬁc for complex I (A) and complex II (B) were used. Error bars
represent SEM. Statistical signiﬁcance (p < 0.05) denoted as: *comparing infarct to nonischemic territory from the same treatment group, and
#comparing infarct tissue harvested from the P188 group with infarct tissue from all other groups. Abbreviations as in Figure 1.
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230INFARCT SIZE AND TROPONIN RELEASE ARE
REDUCED WITH P188 TREATMENT. Infarct size, as a
percentage of area at risk, was signiﬁcantly reduced
with immediate IC P188 infusion compared with con-
trol, delayed P188, and PEG treatment animals (13.9%
vs. 41.1%, 42.8%, and 45.6%, respectively; p < 0.001)
(Figures 6A to 6D). The infarct size with control,
delayed P188, and PEG treatments were not signiﬁ-
cantly different. Serum cTnI was signiﬁcantly
reduced at 4 h in the P188-treated animals as
compared with the control, delayed P188, and PEG
groups (19.2 mg/l vs. 77.4, 68.8, and 65.1 mg/l,
respectively; p < 0.05) (Figure 6E). There were no
signiﬁcant differences between the control, delayed
P188, and PEG groups.
SAFETY ENDPOINTS. Ventricular arrhythmias including
ventricular tachycardia and ventricular ﬁbrillation
occurred in 18% of animals overall. Of the ventricular
arrhythmias, 40% developed during ischemia,
whereas 60% occurred during reperfusion. There were
no signiﬁcant differences between treatment groups.
All animals achieved return of spontaneous circula-
tion and completed the 4-h reperfusion time. Angi-
ography was performed immediately after deﬂation of
the coronary balloon and before medication infusion,
demonstrating Thrombolysis In Myocardial Infarction
ﬂow grade 3 and similar myocardial blush in all ani-
mals. There were no signiﬁcant differences in creati-
nine levels between groups at baseline or 4 h after
reperfusion. The 4-h creatinine values for control,
P188, delayed P188, and PEG groups were 1.1, 1.2, 0.96,
and 1.1 mg/dl, respectively.DISCUSSION
This study reports a signiﬁcant reduction in cardiac
injury with decreased infarct size and preserved
mitochondrial function after STEMI using a ﬁrst-in-
class membrane stabilizing block copolymer called
P188. These ﬁndings highlight the importance of
copolymer delivery route and timing to achieve
meaningful myocardial preservation in reperfusion, as
we ﬁnd that immediate and direct IC infusion, but not
delayed peripheral delivery, is essential to prevent
myocardial injury. These ﬁndings may help explain
the negative outcomes of the CORE trial, which
applied a delayed and peripheral delivery strategy in
an era when thrombolysis was widely used.
Previous studies have proposed 2 distinct mecha-
nisms for the effects of P188. The ﬁrst, altered blood
viscosity leading to improved tissue perfusion, is not
the primary mechanism, as PEG infusion fails to
provide a similar beneﬁt despite similar viscosity
effects. The second proposed mechanism involves
reduction in reperfusion injury through stabilization
of sarcolemmal membranes damaged by the meta-
bolic derangements of ischemia (11,12). Although this
mechanism was not tested directly in the current
study, it may be supported by the improvement in
mitochondrial calcium retention capacity observed.
Direct effects of P188 on mitochondria in situ have
not been shown in prior studies and are beyond the
scope of the current study. Further studies will be
required to elucidate the speciﬁc mechanism of
the beneﬁt.
FIGURE 6 Infarct Size
(A) Hearts were stained in vivo with 2,3,5 triphenyltetrazolium chloride and Evans Blue dye. The hearts were sliced in 1-cm slices revealing
infarct (white), area at risk (red), and nonischemic tissue (blue). Representative slices for control (B) and P188 (C) animals are shown. Infarct
size as a percent of area at risk in all slices from control (n ¼ 6), P188 (n ¼ 7), delayed P188 (n ¼ 6), and PEG (n ¼ 6) groups is quantiﬁed (D).
Serum troponin levels at 4 h of reperfusion were quantiﬁed (E). Error bars represent SEM. #Statistical signiﬁcance (p < 0.05) comparing the
P188 group to all other groups.
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231Ischemia-reperfusion has previously been shown
to reduce mitochondrial respiration predominantly
at complex I in agreement with the current ﬁndings
(17). This down-regulation may be due to damage
incurred by the respiratory complex, or it may be a
result of controlled inhibition of complex I activity
possibly reducing the formation of reactive oxygen
species that can occur at complex I (18). This study
demonstrates near normalization of complex I activ-
ity with P188 treatment. The signiﬁcant improvement
in mitochondrial yield further supports the hypoth-
esis that mitochondrial health is improved with P188treatment. Although serving as a marker of mito-
chondrial health, preserved complex I function may
also provide signiﬁcant bioenergetic beneﬁts for
mitochondria experiencing the severe stress of
ischemia-reperfusion.
Uncontrolled calcium inﬂux during ischemia-
reperfusion presents a severe challenge to the mito-
chondria with calcium overload leading to mPTP
opening, loss of membrane potential, cessation of
respiration, and release of pro-apoptotic factors. Im-
mediate IC P188 treatment demonstrated signiﬁcant
improvement in calcium retention in the infarct
TABLE 1 Comparison of the CORE Trial and the Current Study
CORE Trial Current Study
Human patients with STEMI Translational study with a
porcine STEMI model
Thrombolytic therapy Primary angioplasty
Reperfusion in 54% of patients 100% reperfusion
P188 infused via peripheral IV
P188 delivered w30 min after
reperfusion
Intracoronary P188 infusion
P188 infused immediately
upon reperfusion
No clinical beneﬁt observed 66% reduction in infarct size
Preserved mitochondrial function
Renal dysfunction in P188-
treated patients
No renal dysfunction early after
treatment with puriﬁed P188
CORE ¼ Collaborative Organization for RheothRx Evaluation.
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232tissue without any signiﬁcant effect in the non-
ischemic tissue. The mechanism of improved calcium
retention is unclear, but it may indicate that P188 is
preventing mitochondrial calcium loading in an
injury-dependent manner. Importantly, the group
receiving delayed peripheral P188 infusion did not
demonstrate any of these beneﬁts, suggesting that
early and direct infusion was critically important.
The CORE trial, a phase II, open-label clinical trial
published in 1997, tested the safety and potential
beneﬁts of P188 in 2,948 STEMI patients receiving
thrombolytic therapy (13). No clinical beneﬁt was
observed. However, multiple signiﬁcant limitations
to the protocol can now be observed (Table 1). First,
P188 was delivered by peripheral IV approximately
30 min after thrombolytic therapy was administered.
Although the detailed timing is not described in the
published study, the CORE trial protocol recom-
mended randomization within 15 min of thrombolytic
infusion with initiation of the P188 within 15 min of
randomization. This provides a 30-min delay in P188
therapy from the time of revascularization. Prior
studies using cyclosporine, known to prevent reper-
fusion injury by inhibiting opening of the mPTP in the
setting of cardiac arrest, have shown a severe degra-
dation in efﬁcacy of treatment within as little as 3 min
after return of spontaneous circulation (19). There-
fore, the 30-min delay in the CORE trial may have
negated the opportunity to attenuate reperfusion
injury. In contrast, our study demonstrates a 68%
reduction in infarct size when a similar dose of P188
was delivered directly into the affected coronary ar-
tery immediately after reperfusion.
Use of primary percutaneous coronary intervention
(PCI) in the current study represents the current
standard of care for STEMI patients in the United
States where catheterization laboratories are avail-
able. Until recently, thrombolytic therapy was
the standard treatment modality for patientsexperiencing myocardial infarction. However, 26% of
patients failed to achieve reperfusion even in recent
trials (20). In the CORE trial, which exclusively
enrolled patients receiving thrombolytic therapy,
46% of control subjects did not achieve revasculari-
zation after administration of the thrombolytic. If
reperfusion is never achieved, treatments that pre-
vent reperfusion injury will be ineffective. PCI has
been shown to result in normal coronary artery ﬂow
in over 90% of patients (20). Although absolutely
necessary, reinitiation of coronary ﬂow increases the
potential for reperfusion injury, creating a need for
innovative therapies to prevent this damage (4).
Although myocardial infarction is the most com-
mon cause of ischemia/reperfusion injury, other
medical scenarios trigger similar pathology, including
organ transplantation, cardiac surgery using car-
dioplegia, and cardiac arrest. Other organ systems can
also be affected in situations of stroke or cardiac ar-
rest. P188 was recently tested in combination with
other pharmacological and mechanical treatments for
ischemia/reperfusion injury in a porcine model of
prolonged ventricular ﬁbrillation cardiac arrest,
where it showed considerable improvement in car-
diac function and neurologically intact survival (21).
P188 has also shown a direct beneﬁt in neurons
exposed to ischemia with prevention of apoptosis and
preservation of the blood-brain barrier (22,23).
The CORE trial discovered a signiﬁcant reduction
in the renal function of patients receiving P188. This
was particularly prominent in elderly patients and in
those with pre-existing renal disease. Subsequent
studies have demonstrated a reduction in the renal
effects of P188 when the compound is puriﬁed to
reduce low molecular weight contaminants (24). The
P188 used in our study was highly puriﬁed in its
commercial form, presumably limiting the renal
effects. No difference was observed in creatinine after
4 h of treatment, although renal dysfunction may not
materialize until later in the course and must be
studied further.
STUDY LIMITATIONS. First, this study does not
elucidate a clear mechanism of action for P188.
Further, although the dose was chosen on the basis of
that used in prior animal studies and the CORE trial,
dose optimization was not undertaken. It is clear from
our study that timing and route of delivery have a sig-
niﬁcant effect on outcomes, possibly due to the higher
effective dose when delivered directly into the coro-
nary arteries. Although this suggests that a signiﬁ-
cantly higher systemic dose may provide a similar
beneﬁt if delivered early in reperfusion, potential side
effects of treatmentmay also becomemore prominent.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: STEMI causes
signiﬁcant morbidity and mortality. Reperfusion injury, the injury
induced by reconstitution of blood ﬂow into the ischemic area,
accounts for as much as 50% of the myocardial injury. Treatment
at the time of reperfusion provides an opportunity to prevent
this injury.
TRANSLATIONAL OUTLOOK: Although the mechanism re-
mains unknown, P188 provides a signiﬁcant reduction in reper-
fusion injury in this porcine model of STEMI. Further studies are
required to assess the long-term outcomes after P188 treatment
in animals. Subsequent studies should focus on human trials.
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233Important differences also remain when comparing
this pre-clinical porcine model system to human pa-
tients. First, this model requires the presence of
inhaled anesthetic to maintain animal comfort. This
would be expected to mask the effects of P188, as the
inhaled anesthetic itself may have pre- and post-
conditioning beneﬁts in all animal groups studied
(16,25). However, this would be clinically relevant in
the setting of cardiac surgery and transplant. The
demonstrated beneﬁt with P188 may, therefore, be an
underestimate of its true beneﬁt in the typical STEMI
patient population. In addition, the animals do not
have underlying comorbidities, which often accom-
pany coronary artery disease and may alter the ben-
eﬁts of P188.
Last, this study is limited in the duration of follow-
up, with up to 4 h of monitoring post-P188. Further
studies with longer follow-up would need to be per-
formed to assess renal function and cardiac beneﬁt.
These studies would not be expected to demonstrate
a signiﬁcant reduction in beneﬁt, as the early pre-
dictors of infarct size and cTnI release are well-
established to correlate with long-term outcomes.
CONCLUSIONS
This study demonstrates a substantial cardiac beneﬁt
of P188 after STEMI using a clinically relevanttreatment strategy of IC infusion of P188 at the time
of reperfusion. The model is clinically relevant,
incorporating PCI similar to the current standard of
care in human patients. The results demonstrate that
early IC infusion is critical to achieving the beneﬁt.
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